Beta-Lactamase-Responsive Hydrogel for Targeted Antibiotic Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The continuous emergence and rapid spread of antibiotic-resistant bacteria, particularly those producing β-lactamases, has made it difficult to treat bacterial infections effectively, as these enzymes hydrolyze β-lactam antibiotics, leading to increased antibiotic resistance and treatment challenges.
Innovation Solution
Development of supramolecular hydrogels with β-lactamase-responsive degradation, featuring an AAm/NVP interpenetrating polymer network cross-linked by β-lactam/adamantane-containing guest molecules, which self-heal and selectively degrade in the presence of β-lactamases or β-lactamase-producing bacteria, releasing encapsulated nanoparticles for targeted drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-lactam antibiotics are used extensively to treat bacterial infections, then treatment effectiveness is improved, but β-lactamase-mediated hydrolysis of the antibiotics increases, leading to antibiotic resistance
Solution Approach 1:
The invention converts the harmful β-lactamase enzyme into a useful trigger for drug delivery. The hydrogel incorporates β-lactamase-cleavable crosslinkers that are specifically hydrolyzed by the bacteria's own β-lactamase enzyme, converting the resistance mechanism into a trigger for localized antibiotic release from the hydrogel, thereby treating the infection caused by resistant bacteria.
Solution Approach 2:
The hydrogel acts as an intermediary system between the β-lactamase enzyme and the antibiotic treatment. The β-lactamase-cleavable crosslinker serves as a molecular intermediary that is specifically recognized and hydrolyzed by β-lactamase, triggering the degradation of the hydrogel network and subsequent release of encapsulated antibiotics directly at the infection site.
2Ease of operation
If supramolecular hydrogels with host-guest interactions are used for drug delivery, then controlled release is improved, but degradation specificity in the presence of β-lactamase must be maintained
Solution Approach 1:
The hydrogel employs local quality by incorporating β-lactamase-cleavable crosslinkers specifically at strategic positions within the network. These crosslinkers contain β-lactam moieties that are locally susceptible to β-lactamase hydrolysis, while the rest of the hydrogel matrix maintains its supramolecular structure through host-guest interactions, enabling both controlled release and degradation specificity.
Solution Approach 2:
The hydrogel is a composite material combining supramolecular components (host-guest interactions between cyclodextrin and adamantane) with chemically responsive elements (β-lactamase-cleavable crosslinkers). This composite structure integrates the mechanical stability and controlled release properties of supramolecular gels with the enzyme-responsive degradation capability, achieving both functions simultaneously.
3Reliability
If the hydrogel degrades in response to β-lactamase, then targeted antibiotic release is improved, but the hydrogel structure must remain stable under physiological conditions
Solution Approach 1:
The hydrogel is pre-assembled with β-lactamase-cleavable crosslinkers in a stable supramolecular network before encountering the bacteria. The host-guest interactions between cyclodextrin and adamantane are established in advance to provide structural stability under physiological conditions, while the β-lactam moieties remain latent until specifically triggered by β-lactamase at the infection site.
Solution Approach 2:
The hydrogel exhibits dynamic behavior, transitioning from a stable, intact network under physiological conditions to a degrading, drug-releasing state upon β-lactamase exposure. The supramolecular crosslinks maintain stability through reversible host-guest interactions, while the β-lactamase-cleavable crosslinkers provide a dynamic trigger point that converts structural stability into controlled degradation and antibiotic release when the enzyme is present.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogels provide a platform for bacteria-triggered drug delivery, enhancing infection treatment by localizing antibiotic release, reducing unnecessary exposure, and potentially lowering susceptibility to antibiotic resistance development.
Implementation Method 1
β-lactamase-mediated hydrolysis of β-lactam antibiotics (e.g., penicillins, cephalosporins, monobactams, and carbapenems) is the most common mechanism of resistance
Implementation Method 2
The hydrogel contains an AAm/NVP interpenetrating polymer network (IPN) with supramolecular cross-linkers assembled from β-lactam/adamantane-containing guest molecule with host polymer
Data Source
AI summary
The invention provides a “host-guest” supramolecular hydrogel. The hydrogel contains an AAm/NVP interpenetrating polymer network (IPN) with supramolecular cross-linkers assembled from β-lactam/adamantane-containing guest molecule with host polymeric cyclodextrin (PCD). An advantage of this hydrogel is that because of the molecular association of polymeric cyclodextrin and adamantane, the supramolecular hydrogels self-heal without any external stimuli after the hydrogels are severed. The invention also provides methods of making the hydrogel, methods of making the synthesis intermediates, and methods of diagnosis or treatment of β-lactamase-containing bacteria.